Resonance Health LtdASX: RHT

Liver Fibrosis Device - EPoC Study Results

· Issued by Resonance Health Ltd via ASX

Filed with ASX · · 5 pages · English

Summary by 6ix AI

Resonance Health Ltd has released preliminary results from its extended proof-of-concept study for its non-invasive MRI liver fibrosis device, FibrosisAssessment, which aims to measure liver fibrosis without invasive procedures or expensive hardware. The results indicate that the device's accuracy is comparable to the widely used FibroScan ultrasound device for detecting significant fibrosis. The company plans to refine the model further and seek regulatory feedback as it moves towards commercialization.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

ASX Announcement – 27 October 2026 LIVER FIBROSIS RESULTS OPEN UP GLP-1 BIOMARKER OPPORTUNITY Highlights • FibrosisAssessment aims to measure fibrosis in the liver using MRI sequences without expensive hardware or invasive contrast injections • Fibrosis in the liver is a key biomarker...

Resonance Health Ltd on 6ix

Earlier from Resonance Health

Later from Resonance Health

All Resonance Health news releases